Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

December 5, 2018December 5, 2018

Opdivo-Chemo Combo Doubles Survival Rates in Relapsed or Refractory Leukemia Patients, Phase 2 Trial Shows

News

A combination of Opdivo (nivolumab) and standard Vidaza (azacitidine) chemotherapy reduced the tumor burden in one-third of acute myeloid leukemia (AML) patients and doubled survival rates over patients treated with ... Read more

November 28, 2018

Opdivo Cancer Treatment Safe for HIV Patients on Antiretrovirals, Study Suggests

News

Patients with human immunodeficiency virus (HIV) may safely receive immune checkpoint inhibitors as a cancer treatment, as long as they continue taking antiretroviral therapies, a retrospective study shows. Findings ... Read more

November 27, 2018November 27, 2018

Opdivo-Yervoy Combo Delays Need for Additional Treatment in Renal Cell Carcinoma Patients, Phase 3 Data Shows

News

A combination of Opdivo (nivoumab) and Yervoy (ipilimumab) significantly delayed the need for a subsequent treatment in patients with advanced or metastatic renal cell carcinoma who had not previously ... Read more

November 9, 2018November 9, 2018

Keytruda Elicits Complete Response in 40% of Group of High-risk Bladder Cancer Patients, Early Phase 2 Trial Data Show

News

The immune checkpoint inhibitor Keytruda (pembrolizumab) completely eliminated tumors in almost 40% of a group of bladder cancer patients in an ongoing Phase 2 trial, Merck (known as MSD ... Read more

October 26, 2018

Opdivo-Yervoy Combo Shows Potential as First-line Treatment for Certain Colorectal Cancers

News

A combination of Bristol-Myers Squibb‘s Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) induced promising and durable response rates in metastatic colorectal cancer patients with certain genetic abnormalities who had not received ... Read more

October 9, 2018

Sintilimab Shows Promising Response Rates in Advanced NSCLC Patients with High Mutation Burden

News

Treatment with sintilimab, Innovent‘s PD-1 inhibitor, induces high response rates in non-small cell lung cancer (NSCLC) patients who have failed at least one prior treatment, particularly in those with a ... Read more

October 3, 2018October 3, 2018

FDA Approves Libtayo, First Treatment for Advanced Cutaneous Squamous Cell Carcinoma

News

The U.S. Food and Drug Administration has approved the immune checkpoint inhibitor Libtayo (cemiplimab-rwlc) for advanced cutaneous squamous cell carcinoma (CSCC) — a type of skin cancer — making ... Read more

September 18, 2018September 18, 2018

Targeting Tumor Microenvironment Could Improve Response to Immunotherapies in Urothelial Cancer, Study Finds

News

The cells that support tumors — generally called stromal cells — play a significant part in the resistance to immune checkpoint inhibitor therapies seen in some urothelial cancers, according to a ... Read more

September 14, 2018September 14, 2018

Keytruda and Chemotherapy Combo Now 1st-Line Treatment for Advanced NSCLC in EU

News

The European Commission approved the use of Keytruda (pembrolizumab), in combination with Alimta (pemetrexed) and platinum-based chemotherapy, as a first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC). The approval is ... Read more

June 2, 2017June 6, 2017

Triple Immunotherapy Combo to Be Tested in Trial with Bladder Cancer Patients

News

Two immunotherapies, INO–5401 and INO–9012, will be combined with immune checkpoint inhibitor Tecentriq (atezolizumab) in a Phase 1/2 trial to test the combo’s safety and effectiveness in treating advanced ... Read more

Pin It on Pinterest